{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/630e07bea839d60014dfb735/63866b35ba08230010caa447?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Myositt del 2b: antisyntetasesyndrom","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/630e07bea839d60014dfb735/1666189581862-5d71f840859a886c4750316fe150711f.jpeg?height=200","description":"<p>Oversiktsepisode. Myositt del 2a: antisyntetasesyndrom. Gjest: Marte Sæverås, lungelege og seksjonsoverlege ved Diagnostisk senter, Stavanger universitetssjukehus.</p><p><br></p><p>Autoantistoff omtalt i episoden: anti-Jo1, anti-PL7, anti-PL12, anti-OJ, anti-EJ, anti-KS, anti-Zo, anti-Ha</p><p><br></p><p>Abstract om <a href=\"https://acrabstracts.org/abstract/cancer-screening-recommendations-for-patients-with-idiopathic-inflammatory-myopathy/?fbclid=IwAR0wdASD4SZ2F54QRy44N7_GOfHEMacOl4GQFzVZ-73sAUyuq9ijFu2Xi9M\" rel=\"noopener noreferrer\" target=\"_blank\">internasjonale anbefalinger for malignitetsscreening ved idiopatisk inflammatorisk myopati</a>.</p><p><br></p><p>(Første sesong av podcasten er finansiert av Norsk revmatologisk forening)</p>","author_name":"Jens Vikse"}